Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2019-11-02 Proxy Solicitation & In…
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, as indicated by the header and references to Rule 14a-101 and Section 14(a) of the Securities Exchange Act of 1934. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals to be voted on such as election of directors, amendments to equity incentive plans, reverse stock split, ratification of auditors, and advisory votes on executive compensation. The document also contains governance information about board committees and director independence. It explicitly states it is a proxy statement and includes proxy solicitation details. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or a brief summary. Therefore, the correct classification is PSI with high confidence.
2019-11-02 English
TITAN PHARMACEUTICALS, INC.
Major Shareholding Notification
2019-10-22 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an underwriting agreement for a public offering of units, including details about the offering, warrants, and compliance with Nasdaq listing requirements. It also includes references to exhibits such as the underwriting agreement and a press release. There are no comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. The document is not a full financial report but an announcement of a significant financing event and related corporate developments. Therefore, it fits the category of Capital/Financing Update (CAP).
2019-10-18 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(5) related to a securities offering. It describes the offering of units consisting of common stock and warrants, including pricing, underwriting details, use of proceeds, risk factors, and company overview. The document is not a financial report, earnings release, or management discussion, but rather a capital raising disclosure document. It fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through a securities offering prospectus.
2019-10-17 English
Regulatory Filings 2019
Regulatory Filings
2019-10-17 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-1 for Titan Pharmaceuticals, Inc. It is a request for acceleration of the effectiveness of the registration statement for a proposed offering. The letter is from the underwriter confirming compliance with relevant rules. The document is short (977 characters) and is related to a capital raising process but is not a financial report or earnings release. It is an update related to financing activities, specifically a capital raising registration statement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-10-11 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.